NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to acquire German diagnostics firm Brahms for €330 million ($471 million) in a deal that will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.